SRPX2蛋白表达对晚期胃癌S-1联合奥沙利铂化疗疗效和预后的影响  

Effect of SRPX2 protein expression on efficacy and prognosis of advanced gastric cancer that treated by S-1 combined with oxaliplatin

作　　者：高振远[1] 王雅萍[1] 石默晗 周海荣[1] 陈娟[1] 李雷[2] GAO Zhen-yuan(Department of Oncology,the first affiliated hospital of Bengbu Medical College,Bengbuy Anhui,233004,China.)

机构地区：[1]蚌埠医学院第一附属医院肿瘤内科,安徽蚌埠233004 [2]蚌埠医学院第一附属医院胃肠外科,安徽蚌埠233004

出　　处：《齐齐哈尔医学院学报》2019年第20期2509-2512,共4页Journal of Qiqihar Medical University

摘　　要：目的 检测晚期胃癌组织中含sushi重复蛋白X连锁2(sushi repeat containing protein x linked 2,SRPX2)的表达,分析SRPX2的表达与S-1联合奥沙利铂化疗疗效及患者预后的相关性。方法选取2016年1月-2018年1月蚌埠医学院第一附属医院收治的40例接受含S-1和奥沙利铂为基础化疗的晚期胃癌患者作为研究对象,免疫组织化学法检测胃癌组织中SRPX2蛋白的表达水平,分析SRPX2的表达与化疗疗效、无进展生存期(progression free survival,PFS)和总生存期(overall survival,OS)的关系。结果 40例患者接受含S-1和奥沙利铂为基础的化疗,化疗疗效达完全缓解(complete response,CR) 0例、部分缓解(partial response,PR) 11例、稳定(stable disease,SD) 17例、进展(progression disease,PD) 12例,疾病控制率(disease control rate,DCR)=CR+PR+SD为70.00%(28/40),SRPX2阴性表达组DCR为93.33%,SRPX2阳性表达组DCR为56.00%,两者比较差异具有统计学意义(χ~2=4.57,P<0.05)。SRPX2阴性表达组患者的中位PFS和OS分别为7.6个月和11.7个月,SRPX2阳性表达组患者的中位PFS和OS分别为4.9个月和8.9个月,SRPX2阴性表达组较阳性表达组的PFS和OS均延长,差异有统计学意义(PFS:P=0.015;OS:P=0.042)。结论 晚期胃癌组织中SRPX2的表达与S-1和奥沙利铂为基础的化疗疗效及预后具有相关性,阴性表达组的化疗疗效及生存预后好于阳性表达组,可为临床上晚期胃癌个体化治疗的制定及判断预后提供参考。Objective To detect the expression of sushi repeat containing protein X-linked 2(SRPX2 in advanced gastric cancer tissues,and to analyze the correlation between the expression of SRPX2 and the efficacy and prognosis of advanced gastric cancer that treated by S-1 combined with oxaliplatin.Methods 40 patients of advanced gastric cancer those who received S-1 and oxaliplatin-based chemotherapy in the first affiliated hospital of Bengbu Medical College from January 2016 to January 2018 were selected as study objects.The expression of SRPX2 protein in gastric cancer tissues was detected by immunohistochemistry assay.The relationship between the expression of SRPX2 and the efficacy of chemotherapy,the progression free survival(PFS)and the overall survival(OS)were analyzed.Results 40 patients received chemotherapy based on S-1 and oxaliplatin.The efficacy of chemotherapy:complete response(CR)in 0 case,partial response(PR)in 11 cases,stable disease(SD)in 17 cases,progression disease(PD)in 12 cases,disease control rate(DCR)reached 70.00%(CR+PR+SD,28/40),DCR was 93.33%in the SRPX2 negative expression group and it was 56.00%in the SRPX2 positive expression group,the difference of DCR between the two group was statistically significant(χ2=4.57,P<0.05).The median PFS and OS of SRPX2 negative expression group were 7.6 months and 11.7 months respectively,while those of SRPX2 positive expression group were 4.9 months and 8.9 months respectively.The PFS and OS of SRPX2 negative expression group were longer than those in SRPX2 positive-expression group,differences between the two group was statistically significant(PFS:P=0.015;OS:P=0.042).Conclusions The expression of SRPX2 in advanced gastric cancer is correlated with the efficacy and prognosis of S-1 and oxaliplatin-based chemotherapy,and the survival and prognosis of negative-expression group are better than that of positive-expression group.It could provide reference for the formulation of individualized treatment and prognosis judgment of advanced gastric cancer in clinical.

关 键 词：SRPX2 奥沙利铂 替吉奥 晚期胃癌 疗效 预后 

分 类 号：R735.2[医药卫生—肿瘤]